RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T18:55:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -191.84900M | -177.99100M | -120.77700M | -95.41900M | -68.88900M |
| Minority interest | 0.00000M | -0.01100M | -0.12600M | -0.23300M | -0.55500M |
| Net income | -192.27800M | -178.29700M | -121.12200M | -75.81800M | -68.33400M |
| Selling general administrative | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 111.30M | 110.70M | 118.19M | 102.43M | 84.45M |
| Reconciled depreciation | 20.56M | 17.64M | 13.37M | 9.61M | 2.36M |
| Ebit | -221.84300M | -200.97500M | -142.92100M | -114.78700M | -79.50900M |
| Ebitda | -201.28100M | -183.33700M | -129.55200M | -105.18000M | -77.15000M |
| Depreciation and amortization | 20.56M | 17.64M | 13.37M | 9.61M | 2.36M |
| Non operating income net other | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M |
| Operating income | -201.28100M | -183.33700M | -129.55200M | -105.18000M | -77.15000M |
| Other operating expenses | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M |
| Interest expense | -9.43200M | 23.00M | 22.27M | 0.00000M | 0.00000M |
| Tax provision | 0.43M | 0.31M | 0.34M | 0.00000M | 0.00000M |
| Interest income | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M |
| Net interest income | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.43M | 0.31M | 0.34M | -19.60100M | 8.26M |
| Total revenue | 111.30M | 110.70M | 118.19M | 102.43M | 84.45M |
| Total operating expenses | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M |
| Cost of revenue | - | - | - | 145.92M | 114.87M |
| Total other income expense net | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -192.27800M | -178.29700M | -121.12200M | -95.41900M | -68.88900M |
| Net income applicable to common shares | -192.27800M | -178.28600M | -120.99600M | -95.18600M | -68.33400M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 165.32M | 562.51M | 721.92M | 938.55M | 637.52M |
| Intangible assets | - | 50.73M | 53.76M | 58.13M | 53.16M |
| Earning assets | - | - | - | - | - |
| Other current assets | 12.00M | 18.22M | 15.86M | 11.99M | 5.41M |
| Total liab | 82.43M | 267.55M | 346.58M | 441.18M | 204.78M |
| Total stockholder equity | 82.89M | 294.96M | 375.34M | 497.37M | 432.74M |
| Deferred long term liab | - | 6.27M | 6.64M | 7.18M | 6.57M |
| Other current liab | 27.88M | 33.39M | 28.39M | 30.66M | 21.28M |
| Common stock | 1.78M | 1.67M | 1.46M | 1.42M | 1.16M |
| Capital stock | 1.78M | 1.67M | 1.46M | 1.42M | 1.16M |
| Retained earnings | -1406.37600M | -1148.54500M | -956.26700M | -777.98100M | -656.98500M |
| Other liab | - | 116.85M | 174.64M | 259.24M | 93.71M |
| Good will | 0.00000M | 37.55M | 39.70M | 42.80M | 39.27M |
| Other assets | 0.00000M | 18.52M | 16.82M | 15.06M | 10.57M |
| Cash | 45.20M | 100.44M | 178.87M | 131.33M | 80.43M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 47.73M | 111.71M | 127.89M | 143.55M | 69.87M |
| Current deferred revenue | - | 51.78M | 85.71M | 96.64M | 38.71M |
| Net debt | -7.10000M | -57.33600M | -130.79100M | -89.24300M | -36.02200M |
| Short term debt | 4.59M | 4.12M | 4.03M | 3.69M | 3.21M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 38.10M | 43.11M | 48.08M | 42.09M | 44.41M |
| Other stockholder equity | 1492.08M | 1450.24M | 1334.14M | 1268.51M | 1091.01M |
| Property plant equipment | - | 63.53M | 51.52M | 41.32M | 29.93M |
| Total current assets | 94.33M | 300.33M | 398.77M | 659.67M | 405.47M |
| Long term investments | 0.00000M | 29.84M | 88.17M | 50.53M | 21.83M |
| Net tangible assets | - | 206.68M | 281.88M | 397.31M | 340.12M |
| Short term investments | 35.80M | 177.19M | 197.68M | 510.09M | 282.05M |
| Net receivables | 1.33M | 4.47M | 6.36M | 6.26M | 37.59M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | -88.16900M | -50.53000M | -22.51400M |
| Accounts payable | 15.26M | 22.42M | 9.76M | 12.55M | 6.67M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | -0.86800M | 0.18M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4.59500M | -8.40400M | -3.98700M | 5.42M | -2.44900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 1.67M | 1.46M | 1.42M | 1.16M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1148.54500M | -956.26700M | -777.98100M | -656.98500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 16.63M | 12.25M | 10.17M | 7.87M | 4.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 70.99M | 262.18M | 323.15M | 278.88M | 232.04M |
| Capital lease obligations | 38.10M | 43.11M | 48.08M | 42.09M | 44.41M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 158.44M | 79.46M | 271.60M | -256.20900M | -38.86400M |
| Change to liabilities | - | 14.28M | -6.07500M | 18.88M | 3.69M |
| Total cashflows from investing activities | - | 59.28M | 248.20M | -271.62700M | -59.80100M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 14.59M | 84.66M | 32.86M | 153.10M | 142.03M |
| Change to operating activities | - | -6.67100M | -9.24000M | -6.34800M | -0.88900M |
| Net income | -257.83100M | -192.27800M | -178.29700M | -121.12200M | -95.41900M |
| Change in cash | -55.24000M | -78.42800M | 47.54M | 50.90M | -61.99000M |
| Begin period cash flow | 100.44M | 180.37M | 132.83M | 81.93M | 143.92M |
| End period cash flow | 45.20M | 101.94M | 180.37M | 132.83M | 81.93M |
| Total cash from operating activities | -224.84200M | -223.62700M | -233.25100M | 169.88M | -144.40200M |
| Issuance of capital stock | 33.73M | 84.87M | 27.10M | 142.53M | 136.31M |
| Depreciation | 22.19M | 20.56M | 17.64M | 13.37M | 9.61M |
| Other cashflows from investing activities | - | - | -0.11900M | -0.70400M | -0.26200M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | 7.66M | -10.70300M | 4.19M |
| Change to account receivables | 3.15M | 2.33M | -0.78900M | 31.68M | -32.23600M |
| Sale purchase of stock | -1.45300M | -2.10400M | 3.37M | -0.76500M | 2.04M |
| Other cashflows from financing activities | 16.04M | 86.76M | 2.39M | 153.87M | 3.68M |
| Change to netincome | - | 31.65M | 32.90M | 25.93M | 19.40M |
| Capital expenditures | 21.16M | 20.17M | 23.28M | 14.71M | 20.68M |
| Change receivables | - | 1.89M | -0.10300M | 31.33M | -32.54300M |
| Cash flows other operating | - | -90.03500M | -93.96300M | 210.00M | -38.74600M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -79.68200M | 47.81M | 51.35M | -62.17400M |
| Change in working capital | -164.03400M | -82.31900M | -101.89500M | 252.59M | -73.01000M |
| Stock based compensation | 27.36M | 31.65M | 32.96M | 25.71M | 19.33M |
| Other non cash items | 153.80M | -1.24200M | -6.42700M | -0.66600M | 0.22M |
| Free cash flow | -245.99700M | -243.79800M | -256.52900M | 155.16M | -165.07700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics Inc |
-0.035 1.49% | 2.31 | - | - | 0.63 | 1.35 | 0.39 | -0.7145 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
501 Canal Blvd, Richmond, CA, United States, 94804
| Name | Title | Year Born |
|---|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | CEO, Pres & Director | 1963 |
| Ms. Prathyusha Duraibabu CPA, M.B.A. | Sr. VP, CFO & Principal Accounting Officer | 1979 |
| Mr. D. Mark McClung | Exec. VP & COO | 1963 |
| Dr. R. Andrew Ramelmeier Ph.D. | Exec. VP of Technical Operations | 1962 |
| Dr. Jason D. Fontenot Ph.D. | Sr. VP & Chief Scientific Officer | 1970 |
| Ms. Aron Feingold | Head of Corp. Communications & Investor Relations Officer | NA |
| Mr. Scott B. Willoughby | Sr. VP, Gen. Counsel & Corp. Sec. | 1975 |
| Ms. Whitney Jones | Sr. VP & Chief People Officer | NA |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Chief Devel. Officer | NA |
| Ms. Heather Erickson | Chief of Staff | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...